The anticoagulant medication known as Pradaxa (dabigatran), which is used to treat atrial fibrillation and other heart complications, is the subject of a new lawsuit against its manufacturer, Boehringer Ingelheim.
The lawsuit was filed in California Superior Court on July 2 by the wife of a deceased man who is said to have passed away after being treated with the drug. In her lawsuit, the woman claims that the manufacturers downplayed the dangers linked to the pills, which include excessive bleeding. The plaintiff is also accusing the makers of lying while marketing the drug as a safer alternative to other anticoagulants (including Warfarin). McKesson, the distributor of Boehringer Ingelheim’s Pradaxa, is also named in the lawsuit.
According the court documents, the decedent began taking dabigatran in November 2011. By January of the following year he was rushed to the emergency room and diagnosed as having a brain hemorrhage. The court documents state that “his uncontrollable bleeding was caused and/or worsened by his use of Pradaxa.” The plaintiffs says that Boehringer Ingelheim “knew or should have known of the risk of Pradaxa internal bleeding, but failed to adequately warn the public.”
These claims, among others, are why thousands of plaintiffs have sued the manufacturers of Pradaxa. Other drugs are used to treat AF, as well. Common drugs used to treat AF flutters include anticoagulants like Multaq. Multaq is made by Sanofi-Aventis and has been linked to serious side effects including a worsening of the heart condition, liver failure and lung toxicity. It is for this reason that the FDA has recommended that doctors only prescribe Multaq if all other medications fail to work.
If you or a loved one has suffered from liver failure or a worsening heart condition after being treated with Multaq, contact the attorneys at Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.
About Greg Jones Law
You May Also Like